A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

Inclusion Criteria: * Immunocompromised with clinically compatible illness. * Diagnosis of proven or probable or possible Invasive Aspergillosis (based on a modified version of the revised EORTC/MSG consensus definitions). * Diagnosis of infection due to Scedosporium or Fusarium species. * Male and female from 2 to 17 years of age. * Females with childbearing potential must have negative pregnancy test and be using appropriate contraception. Exclusion Criteria: * Allergy or hypersensitivity to the azole drugs. * Female subjects who are pregnant or lactating. * Patients who received more than four days of antifungal drugs to treat the current episode of invasive aspergillosis or rare mold infection. * Received within 24 hours prior to enrollment drugs that may cause QT interval prolongation. * Significant liver, kidney or heart dysfunction. * Not expected to survive for at least 5 days.